Filing Flows

Filing Flows › Gyre Therapeutics (GYRE) › Next earnings date

Gyre Therapeutics (GYRE) earnings: beat the estimate

Gyre Therapeutics (GYRE) reported on Nov 5, 2026 and beat the EPS estimate: −$0.04 against −$0.12 (+65.7%). Revenue was $32.9M for Q3 2026, +0.7% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+65.7% vs estimate
Beat rate60%

The last report

Gyre Therapeutics reported revenue of $32.9M for the third quarter 2026 (+0.7% Y/Y), net loss $2.5M: Gyre Pharmaceuticals $32.4M, Gyre $508K. How it makes money → · Every quarter →

Gyre Therapeutics: EPS against the estimate, last 5 reportsGyre Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.02$0.03Nov 25$0.01$0.05Mar 26−$0.07−$0.10May 26−$0.06−$0.12Aug 26−$0.12−$0.04Nov 26
Latest (Nov 26): Estimate −$0.12, Reported −$0.04.

Gyre Therapeutics' latest quarter

Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Gyre Therapeutics beat earnings?

Gyre Therapeutics (GYRE) reported on Nov 5, 2026 and beat the EPS estimate: −$0.04 against −$0.12 (+65.7%).

When does GYRE report earnings?

The next date is not set yet.

Does Gyre Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.